europe: So while those with the condition in the US and Europe were getting lifesaving treatment, only a handful of the millions across Africa who needed it had access, according to The Guardian. Fast-forward to 2019, and campaigning has resulted in HIV treatment prices dropping from tens of thousands of pounds a year for each patient to about 50, and millions of people across the global south are alive today thanks to cheap, quality-assured generic medicines. In order to maintain their profits, the companies that had developed effective medicines fought hard to prevent the sale of affordable generics. But the problem at the heart of the current model of pharmaceutical innovation has not gone away. At the moment, innovation is incentivised by the profits drug companies can expect to make during the 20-year monopolies they are granted through patents on the medicines they develop. It is endangering the lives of patients in the UK and threatening the sustainability of health systems across the rich and poor worlds.
(news.financializer.com). As
reported in the news.
Tagged under europe, patient topics.